跳至主要内容
临床试验/NCT00273962
NCT00273962已完成4 期

A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation

Boehringer Ingelheim12 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2002年5月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
500
试验地点
12
主要终点
The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment

研究概览

简要总结

To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with salbutamol alone given every 20 minutes for three doses in asthmatic children with severe acute exacerbation

详细描述

A Comparison of Ipratropium 500mcg and salbutamol 2.5mg (Combivent UDV) and salbutamol UDV alone (2.5mg) in a Double-blind, Efficacy and Safety Study in Asthmatic Children with Severe Acute Exacerbation

Study Hypothesis:

Several studies, including a study conducted in an emergency room setting, demonstrated that the addition of ipratropium bromide, an anticholinergic drug, to standard salbutamol therapy significantly improves pulmonary function as compared to salbutamol alone.

Comparison(s):

Ipratropium bromide 500 mcg plus salbutamol 2.5mg (Combivent) vs salbutamol (2.5mg) alone given every 20 minutes for 3 doses

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
2 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment

次要结局

  • Change in asthma severity scores from baseline to end of treatment; number of patients needing hospitalization; number of rescue medications; oxygen saturation, number of discharged patients revisiting the ER/doctors clinic

研究者

申办方类型
Industry

研究点 (12)

Loading locations...

相似试验

A Comparison of Combivent UDV (Ipratropium 500mcg... | 临床试验